Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Written informed consent * ≥ 18 years of age * Untreated non-small-cell lung cancer stage IIIB/IV * Life expectancy \> 3 months * Performance status ECOG 0-2 Exclusion Criteria: * Concurrent systemic immune therapy, chemotherapy or therapy with any anticancer drug not indicated in the study protocol * Any investigational agent(s) within 4 weeks prior to study entry * Previous administration of any EGFR-targeted therapy (antibodies, small molecules and others) * Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information